Game Changing Innovation in Respiratory Medicine:

OmniSpirant Limited was founded by Gerry McCauley in 2016. Gerry qualified as a Master of Pharmacy in 2001. Gerry has extensive commercial knowledge, industry contacts and has built an international network of experts in the fields of cell and gene therapy and respiratory drug delivery.

At OmniSpirant, we believe our technology has the potential to positively impact the lives of millions of patients. We have created a bold new approach to treat currently incurable respiratory diseases that affect hundreds of millions of people worldwide. Our planned pipeline of advanced therapies intersect regenerative medicine and gene therapy in the hope of treating these devastating lung diseases of severely unmet patient need. Our patent pending platform technology (OmniSomes) is based on inhaled bioengineered stem cell exosomes (extracellular vesicles) which are capable of efficient intracellular delivery of a variety of RNA and protein based therapeutic cargoes to effectively treat these diseases at the required level of complexity. Our engineered stem cell exosomes are initially being used to develop first in class regenerative gene therapies for cystic fibrosis (OS001) and lung cancer (OS003). OS003 will be investigated using systemic (intravenous) administration for treating other types of cancer that are believed to be amenable to treatment as they share broadly similar driver mutations. The proprietary mucus penetrating exosomes have similar transformative potential for treating many other respiratory diseases (see our pipeline in Technology section). Please browse our site to learn more about our mission and technology.

Mission

Transforming medicine through the development of first-in-class regenerative gene therapies. 

More information at www.omnispirant.com